Status:
NO_LONGER_AVAILABLE
Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma
Lead Sponsor:
TeneoOne Inc.
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
This is a single patient protocol for TNB-383B in a subject with relapsed/refractory multiple myeloma (MM) who is not a candidate for treatment regimens known to provide clinical benefit in MM.
Eligibility Criteria
Inclusion
- Adequate bone marrow function
- eGFR ≥ 30 mL/min
- Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
- Serum calcium (corrected for albumin) at or below the ULN range
Exclusion
- Candidate for treatment regimens known to provide clinical benefit in MM
- Active infection requiring parenteral anti-infective treatment
- Any medical or psychiatric condition which in the opinion of the investigator or Teneobio Medical Monitor places the subject at an unacceptably high risk for toxicities, could interfere with successful or safe delivery of therapy, or could interfere with evaluation of the investigational product or interpretation of subject safety
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04453397
Last Update
September 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest
Winston-Salem, North Carolina, United States, 27157